Mean Platelet Volume (MPV) for Predicting Prognosis of Rectum Cancer After Neoadjuvant Treatment

Abstract

Background: Rectum cancer is a type of colorectal cancer. Its etiology and etiopathogenesis are similar to other colon diseases. However, it is differentiated from other colon tumors because of its different anatomy and treatment. Although there are previous studies indicating high mean platelet volume (MPV) levels with poor prognosis in colorectal cancers, there is no study evaluating its prognostic value in rectum cancer.Based on this fact, we aimed to evaluate the MPV value for predicting prognosis of rectum cancer patients who treated with neoadjuvant chemotherapy.

         Method: We retrospectively collected the data of 80 operated rectum adenocarcinoma patients who were treated neoadjuvant chemoradiotherapy between 2011 and 2018 in Umraniye Research and Training Hospital and Acıbadem University Medical Oncology Outpatient Clinic.The clinical parameters were recorded at the time of diagnosis such as; histopathological type of cancer (adenocarcinoma or mucinous), histological differentiation, stage, relapse status and localization, presence of metastasis, total lymph node numbers.Peripheral venous blood samples were collected for analysis of of MPV, lymphocyte (Lym), neutrophile (Neu) and platelet (Plt) numbers,, hemoglobin levels and carcinoembryonic antigen (CEA) levels at the time of diagnosis. MPV was investigated as prognostic factors for disease free survival

        Findings: This study included 80 rectum cancer patients and 55 were male (68,8%). Median age was 56 (range 22 to 83 years). According to clinical parameters, histopathological types were adenocarcinoma in 75 (93,8%) patients and mucinous type in 5 (6,2%) patients). In multivariate analysis, MPV were  found to be independent prognostic factors for disease free survival (p 0.02).

 Interpretation: According to our study, we suggest that high levels of MPV at the time of diagnosis can be used as a predictive biomarker for rectum patients who may show relapse predisposition

Keywords

• Rectum cancer,mean platelet volume,disease free survival

Rektum Kanserinin Prognozunu Öngermede Ortalama Trombosit Hacmi (MPV)'nin Rolü

Öz

Amaç: Rektum kanseri, bir kolorektal kanser türüdür. Etiyolojisi ve etiyopatogenezi diğer kolon hastalıklarına benzer. Bununla birlikte, farklı anatomisi ve tedavisi nedeniyle diğer kolon tümörlerinden ayrılır. Kolorektal kanserlerde prognozu kötü olan yüksek ortalama trombosit volümü (MPV) düzeylerini gösteren önceki çalışmalar olmasına rağmen, rektum kanserinde prognostik değerini değerlendiren bir çalışma yoktur. Bu nedenle neoadjuvan tedavi alan rezeke rektum kanseri hastalarının prognozunu tahmin etmek için MPV değerini rolünü değerlendirmeyi amaçladık. 

Yöntem: Ümraniye Eğitim ve Araştırma Hastanesi ve Acıbadem Üniversitesi Medikal Onkoloji Polikliniğinde 2011-2010 yılları arasında neoadjuvan kemoradyoterapi alan 80 ameliyatlı rektum adenokarsinomlu hastanın verilerini retrospektif olarak topladık. Klinik parametreler; histopatolojik tip kanser (adenokarsinom veya müsin), histolojik farklılaşma, evre, nüks durumu ve lokalizasyonu, metastaz varlığı, total lenf nodu sayıları. MPV, lenfosit (Lym), nötrofilin (Neu) analizi için periferik venöz kan örnekleri alındı. ve tanı sırasında trombosit (Plt) sayıları, hemoglobin seviyeleri ve karsinoembriyonik antijen (CEA) seviyeleri. MPV, hastalıksız sağkalım için prognostik faktörler olarak araştırıldı.

Bulgular: Bu çalışmaya 80 rektum kanseri hastası dahil edildi ve 55'i erkekti (% 68,8). Ortanca yaş 56 (dağılım 22-83) idi. Klinik parametrelere göre histopatolojik tipler 75 (% 93,8) hastada adenokarsinom, 5 (% 6,2) hastada müsin tip idi. Çok değişkenli analizde MPV'nin hastalıksız sağkalım için bağımsız prognostik faktörler olduğu bulundu (p 0.02).

Sonuç: Çalışmamıza göre, tanı sırasındaki yüksek MPV seviyelerinin nüks yatkınlığı gösterebilecek rektum hastaları için prediktif bir biyobelirteç olarak kullanılabileceğini öneriyoruz.  

Anahtar Kelimeler

• Ortalama trombosit hacmi,rektum kanseri,, hastalıksız sağ kalım

Kaynakça

1. 1. Ross M., Romrell L., Kaye G.I., “Histology: A Text and Atlas”, 3rd Edition, William&Wilkins, 1995; 490,494
2. 2. Sadler T.W. “Medical Embryology’, 6th Edition, Williams&Wilkins, 1990;237-258
3. 3. Hawk ET, Limburg PJ, Viner JL. Epidemiology and prevention of colorectal cancer. Surg Clin N Am 2002;82:905-941.
4. 4. Wiawer SJ, Fletcher RH, Miller L et al. Colorectal cancer screening clinical guidelines and rationale. Gastroenterology 1997;112:594
5. 5. Sandler RS. Epidemiology and risk factors for colorectal cancer. Gastroenteology Clinics of North America 1996;25:717-733.
6. 6. Burt RW. Familial risk and colorectal cancer. Gastroenteology Clinics of North America1996;25:793-805.
7. 7. Pietra N, Sarli L, Sansebastiano G. Prognostic value of ploidy, cell proliferation cinetics and convantionals clinicopathologic criteria in patients with colorectal carcinoma. A prospective study. Dis Colon Rectum 1996; 39:494-503.
8. 8. Bath PM, Butterworth RJ. Platelet size: measurement, physiology and vascular disease. Blood Coagul Fibrinolysis 1996; 7(2): 157-61.

9. 9. Gasparyan AY, Ayvazyan L, Mikhailidis DP, Kitas GD. Mean platelet volume: a link between thrombosis and inflammation?. Curr Pharm Des. 2011; 17(1):47-58.
10. 10. Bancroft AJ, Abel W, et al. Mean trombosit volume is a useful parameter: a reproducible routine method using a modified Coulter Thrombocytometer.Trombosits 2000;11: 379-87
11. 11. Dow RB. The Clinical and laboratory utility of trombosit volume parameters. Jnl Medical Science 1994;15: 1-15.
12. 12. Senaran H, İleri M, Altınbaş A, et al.Thrombopoietin and mean trombosit volüme in coronary artery disease. Clin Cardiol 2001;24:405-408.
13. 13. Sun NC, McAfee WM, Hum GJ, Weiner JM. Hemostatic abnormalities in malignancy, a prospective study of one hundred eight patients. Part I. Coagulation studies. Am J Clin Pathol 1979; 71:10-6.
14. 14. Miller SP, Sanchez-Avalos J, Stefanski T, Zuckerman L. Coagulation disorders in cancer. I. Clinical and laboratory studies. Cancer 1967; 20:1452-65.
15. 15. Pedersen LM, Milman N. Prognostic significance of thrombocytosis in patients with primary lung cancer. Eur Respir J 1996; 9:1826-30.
16. 16. Karagöz B, Sücüllü İ, Sayan Ö, et al. Platelet indices in patients with colorectal cancer. Cent Eur J Med 2010;5:365-8.
17. 17. Kandemir EG, Mayadagli A, Karagöz B, et al. Prognostic significance of thrombocytosis in node negative colon cancer. J Int Med Res 2005;33:228- 35.
18. 18. Aksoy S, Kilickap S, Hayran M, et al. Platelet size has diagnostic predicive value, for bone marrow metastasis in patients with solid tumors. Int J Lab Hematol 2008;30:214-9.
19. 19. Joanna Matowicka-Karna, Zbigniew Kamocki, Beata PoliNska, Joanna Osada, and Halina Kemona Clinical Study Platelets and Inflammatory Markers in Patients with Gastric Cancer. Hindawi Publishing Corporation Clinical and Developmental Immunology Volume 2013, Article ID 401623
20. 20. Baldane S, Ipekci SH, Sozen M, and Kebapcilar L. Mean Platelet Volume Could be a Possible Biomarker for Papillary Thyroid Carcinomas Asian Pac J Cancer Prev 2015, 16 (7), 2671-2674
21. 21. Platelet volume as a parameter for platelet activation in patients with endometrial cancer; T. Oge, O. T. Yalcin, S. S. Ozalp & T. Isikci Journal of Obstetrics and Gynaecology, April 2013; 33: 301–304
22. 22. Polinska B, Matowicka-Karna J, Kemona H. Assessment of the influence of the inflammatory process on the activation of blood platelets and morphological parameters in patients with ulcerative colitis (colitis ulcerosa). Folia histochemica et cytobiologica / Polish Academy of Sciences, Polish Histochemical and Cytochemical Society. 2011;49(1):119-24.
23. 23. Kapsoritakis AN, Koukourakis MI, Sfiridaki A, Potamianos SP, Kosmadaki MG, Koutroubakis IE et al. Mean platelet volume: A useful marker of inflammatory bowel disease activity. Am J Gastroenterol. 2001;96(3):776-81.
24. 24. Yuksel O, Helvaci K, Basar O, Koklu S, Caner S, Helvaci N et al. An overlooked indicator of disease activity in ulcerative colitis: mean platelet volume. Platelets. 2009;20(4):277-81. 25. Kisacik B, Tufan A, Kalyoncu U, Karadag O, Akdogan A, Ozturk MA, et al. Mean platelet volume (MPV) as an inflammatory marker in ankylosing spondylitis and rheumatoid arthritis. Joint Bone Spine. 2008;75(3):291-4.26. Aktas G, Sit M, Tekce H, Alcelik A, Savli H, Simsek T, et al. Mean platelet volume in nasal polyps. The West Indian medical journal. 2013;62(6):515-8.
25. 27. Koksal D, Segmen F, Koyuncu A, Atasever M and Berkoglu M. Mean platelet volume: is there a link between stage and venous Thrombosis in non-small cell lung cancer. Solunum Hastalıkları. 2013;24(2):53-57.
26. 28. Wlodarczyk M, Kasprzyk J, Sobolewska Wlodarczyk A, Wlodarczyk J, Tch'orzweski M, Dziki A and Dziki L. Mean platelet volume as a possible biomarker of tumor progression in rectal cancer. Cancer Biomarkers. 2016;17(4):411-417.
27. 29. Yun Z, Zhang X, Liu Y, Liu T, Liu Z, Wang R and Yu K. Lower mean platelet volume predicts poor prognosis in renal cell carcinoma. Scientific Reports. 2017. 30. Shen, XM, Xia YY, Lian L, Zhou C, Li XL, Han SG, Zheng Y, Gong FR, Tao M, Mao ZQ and and Li W. Mean platelet volume provides beneficial diagnostic and prognostic information for patients with resectable gastric cancer. Oncol Lett. 2016;12(4): 2501–2506
28. 31. Tuncel T, Ozgun A, Emirzeoglu L, Celik S, Bilgi O and Karagoz B. Mean platelet volume as a prognostic marker in metastatic colorectal cancer patients treated with Bevacuzimab combined chemotherapy. Asian Pac J Cancer Prev. 2014;15(15);6421-6423.
29. 32. Li ZY, Li Y, Jiang Z, Wang RT and Wang XS. Elevated mean platelet volume is Associated with presence volume is Associated with presence of Colon Cancer. Asian Pac J Cancer Prev. 2014;15(23):10501-10504
30. 33. Ferroni P, Guadagni F, Riondino S, Portarena I, Mariotti S, La Farina F, Davì G, Roselli M. Evaluation of mean platelet volume as a predictive marker for cancer- associated venous thromboembolism during chemotherapy. Haematologica. 2014;99(10):1638-44.
31. 34. Vizioli L, Muscari S, Muscari A.The relationship of mean platelet volume with the risk and prognosis of cardiovascular diseases. Int J Clin Pract. 2009 Oct;63(10):1509-15.
32. 35. Celik T,Yuksel UC,Iyisoy A,Kursakioglu H,Ozcan O ,Kilic S ,et al Effects of nebivolol on platelet activation in hypertensive patients ; a comparative study with metoprolol. Int J Cardiol 116:206-211
33. 36. Demirtunc R, Duman D, Basar M. Effects of doxazosin and amlodipine on mean platelet volume and serum serotonin level in patients with metabolic syndrome: a randomised, controlled study. Clin Drug Investig. 2007;27(6):435-41.